CKAP2 Inhibitors

Cytoskeleton-associated Protein 2 (CKAP2) inhibitors are focused on targeting cellular mechanisms related to microtubule dynamics and p53/TP53-mediated cellular processes, indirectly affecting CKAP2's function. Microtubule-targeting agents such as Taxol, Vinblastine, Nocodazole, and Colchicine are critical as they influence microtubule stability and assembly. These agents can potentially impact CKAP2's role in microtubule dynamics and cell cycling. Nutlin-3, a MDM2 antagonist, and Pifithrin-α, a p53 inhibitor, are included due to their potential impact on CKAP2 function via the p53/TP53 pathway, a key regulator of cell cycle and apoptosis.

Wee1 inhibitors, Aurora kinase inhibitors, CDK inhibitors, and PLK1 inhibitors target various aspects of cell cycle regulation and mitotic progression, potentially influencing CKAP2-mediated processes. Kinesin inhibitors, like Ispinesib, affect spindle dynamics during cell division, which could impact CKAP2's function. In summary, the strategy for targeting CKAP2 involves modulating key processes in microtubule dynamics and cell cycle regulation, particularly those involving p53/TP53. The listed inhibitors, by affecting these cellular functions, offer potential routes to indirectly influence CKAP2's activity, considering its crucial role in stabilizing microtubules and regulating cell cycling and death.